Cipher Operating Income from 2010 to 2026
| CPH Stock | CAD 15.21 0.64 4.39% |
Operating Income | First Reported 2004-03-31 | Previous Quarter 5 M | Current Value 5 M | Quarterly Volatility 4.1 M |
Check Cipher Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cipher Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 506.9 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 14.31, Dividend Yield of 0.0458 or PTB Ratio of 5.25. Cipher financial statements analysis is a perfect complement when working with Cipher Pharmaceuticals Valuation or Volatility modules.
Cipher | Operating Income |
Evaluating Cipher Pharmaceuticals's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cipher Pharmaceuticals's fundamental strength.
Latest Cipher Pharmaceuticals' Operating Income Growth Pattern
Below is the plot of the Operating Income of Cipher Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Cipher Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cipher Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cipher Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cipher Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Cipher Operating Income Regression Statistics
| Arithmetic Mean | 5,326,849 | |
| Coefficient Of Variation | 234.35 | |
| Mean Deviation | 8,781,738 | |
| Median | 9,025,200 | |
| Standard Deviation | 12,483,473 | |
| Sample Variance | 155.8T | |
| Range | 57.1M | |
| R-Value | 0.38 | |
| Mean Square Error | 141.9T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | 946,584 | |
| Total Sum of Squares | 2493.4T |
Cipher Operating Income History
About Cipher Pharmaceuticals Financial Statements
Cipher Pharmaceuticals investors utilize fundamental indicators, such as Operating Income, to predict how Cipher Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 9 M | 9.5 M |
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.